What's new with PRISMAP

Thierry Stora, PRISMAP coordinator, will participate in the EURADOS webinar: Challenges and developments in the field of therapeutic radiopharmaceuticals, on Thursday 20 January 2022 at 15h30 CET. Don't miss it!

In 2020 EURADOS published an update of its Strategic Research Agenda (SRA). The updated SRA contains 5 visions which cover the main fields in radiation dosimetry. For each vision challenges and subsequently more detailed research lines are defined. Vision 4: “Towards integrated personalized dosimetry in medical applications” covers the challenges of patient dosimetry in nuclear medicine focussing on both internal dosimetry for pre-clinical development and evaluation of radiopharmaceuticals emitting alpha, beta and auger radiation and implementation of internal dosimetry in clinical practice. Based on SRA vision 4, EURADOS Working Group 7 “internal dosimetry” composes a task group focussing on the development of a roadmap towards a dosimetry model for radionuclide therapy which should provide guidance on the role of EURADOS to address internal dosimetry for therapeutic radiopharmaceuticals. 

To attend: https://www.bigmarker.com/sckcen/EURADOS-webinar-January-2022

We wish you all a happy holiday season and a good start to the year 2022!

New Capability Announcement — Idaho National Laboratory, Radioisotope ElectroMagnetic Isotope Separator

The Department of Energy Office of Isotope Research & Development and Production (DOE Isotope Program) has recently added a new capability into its isotope production network. The Radioisotope Electromagnetic Isotope Separator, or RAD EMIS, located in the Materials and Fuels Complex at Idaho National Laboratory (INL) is now under the stewardship of the DOE Isotope Program. This unique instrument is able to enrich small quantities of rare or short-lived radioisotopes for use in research as radiotracers, national security exercises, and precision analytical measurements as internal standards. More information can be found in the Fall 2021 newsletter of DoE

First PRISMAP call for user projects now open!

We are very pleased to announce our first call for user projects. 

Our users are kindly invited to submit applications online at any time via the PRISMAP online submission service. Applications are reviewed twice a year.

The current cut-off date is 31 March 2022. Hearings with all user projects passing the eligibility threshold will take place on 16 May 2022.

The cut-off date of the following call is foreseen for 30 September 2022.

The project application consists of two parts:

Part A is completed through the application form below. It includes the request for radionuclides and application services, a project overview and administrative information.

Part B contains a description of the proposed scientific user project, to be uploaded below as a PDF fileI It will be submitted together with the application form.

For details, please refer to the Application guidelines.

A first for Switzerland: proton therapy to treat lung cancer

Today, PRISMAP partner Paul Scherrer institute (PSI) and the Radio-Oncology Centre of the Cantonal Hospitals of Aarau and Baden treated the first lung cancer patient with protons as part of an international prospective randomised clinical trial.

A 60-year-old patient suffering from lung cancer received proton beam therapy, a medical procedure where positively charged particles are precisely targeted at the tumour. This is the first time this type of radiotherapy has been used for lung cancer treatment in Switzerland. The 7-week course of treatment is part of an international clinical trial in which the PSI and cantonal hospitals in Aarau are taking part. The PSI already has a wealth of experience in proton therapy and has been successfully treating patients with tumours in the head and neck area, as well as the torso, since 1996. The purpose of the clinical trial is to explore another medical indication: inoperable lung tumours. Medics expect this much less aggressive but more precise form of radiotherapy will have fewer secondary effects on healthy lung tissue and the heart.

Show more posts